- Home
- WINT vs SISI Comparison
WINT vs SISI Comparison
Compare WINT & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- SISI
- Stock Information
- Founded
- WINT 1992
- SISI 1997
- Country
- WINT United States
- SISI China
- Employees
- WINT N/A
- SISI N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- SISI Medicinal Chemicals and Botanical Products
- Sector
- WINT Health Care
- SISI Health Care
- Exchange
- WINT Nasdaq
- SISI Nasdaq
- Market Cap
- WINT 5.3M
- SISI 5.9M
- IPO Year
- WINT 1995
- SISI 2016
- Fundamental
- Price
- WINT $0.50
- SISI $2.62
- Analyst Decision
- WINT Hold
- SISI
- Analyst Count
- WINT 1
- SISI 0
- Target Price
- WINT $18.00
- SISI N/A
- AVG Volume (30 Days)
- WINT 549.5K
- SISI 159.0K
- Earning Date
- WINT 11-26-2024
- SISI 11-14-2024
- Dividend Yield
- WINT N/A
- SISI N/A
- EPS Growth
- WINT N/A
- SISI N/A
- EPS
- WINT N/A
- SISI N/A
- Revenue
- WINT N/A
- SISI $10,330,284.00
- Revenue This Year
- WINT N/A
- SISI N/A
- Revenue Next Year
- WINT N/A
- SISI N/A
- P/E Ratio
- WINT N/A
- SISI N/A
- Revenue Growth
- WINT N/A
- SISI 370.34
- 52 Week Low
- WINT $0.45
- SISI $2.24
- 52 Week High
- WINT $22.32
- SISI $117.65
- Technical
- Relative Strength Index (RSI)
- WINT 27.72
- SISI 36.15
- Support Level
- WINT $0.45
- SISI $2.24
- Resistance Level
- WINT $0.64
- SISI $3.10
- Average True Range (ATR)
- WINT 0.06
- SISI 0.48
- MACD
- WINT 0.07
- SISI 0.11
- Stochastic Oscillator
- WINT 19.50
- SISI 18.84
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.